君实生物公告:公司预计2024年实现营业收入约194,900万元,同比增长29.71%;研发费用预计为127,400万元,同比减少34.24%。归属于母公司所有者的净利润预计为-129,200万元,亏损减少43.42%。业绩预告期间为2024年1月1日至2024年12月31日,数据未经注册会计师审计。公司表示,营业收入增长主要得益于商业化药品销售的提升,特别是特瑞普利单抗的市场表现。公司将继续加强...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.